Related Experiment Video
Updated: Jul 6, 2026
Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
[Clinical experience with efalizumab in the Hospital of Cruces]
Z Martínez de Lagrán1, M R González Hermosa, J L Díaz-Pérez
1Servicio de Dermatología, Hospital de Cruces, Vizcaya, España. ZURINE.MARTINEZDELAGRANALVAREZDEARCAYA@osakidetza.net
Efalizumab (Raptiva) is one of the biological agents approved recently for the treatment of patients with moderate-severe psoriasis who have not responded to conventional treatments. It is a humanized IgG1 monoclonal antibody which, due to its anti-D11 effect, is capable of blocking the endothelial migration and T cell activation on the skin, fundamental processes in the etiopathogeny of psoriasis. We present the experience we have had in our hospital over the last two years with 23 patients who have initiated treatment with efalizumab.
Efalizumab (Raptiva) is one of the biological agents approved recently for the treatment of patients with moderate-severe psoriasis who have not responded to conventional treatments. It is a humanized IgG1 monoclonal antibody which, due to its anti-D11 effect, is capable of blocking the endothelial migration and T cell activation on the skin, fundamental processes in the etiopathogeny of psoriasis. We present the experience we have had in our hospital over the last two years with 23 patients who have initiated treatment with efalizumab.
